Of the 71 patients receiving platinum-based chemotherapy after first-line gefitinib , a partial response was documented in 25.4 % ( 18/71 ) , stable disease in 43.7 % ( 31/71 ) and progression of disease in 21.1 % ( 15/71 ) .